Xbrane Biopharma presents Nomination Committee

Corporate Information

English

Listing Regulation

News

Nomination Committee

Regulatory

In accordance with the principles of the Nomination Committee of Xbrane Biopharma AB ("Company" or "Xbrane"), adopted at the Annual General Meeting (“AGM”) on May 6th, 2021, the Nomination Committee shall consist of four members of whom three shall be nominated by the Company´s three largest shareholders with respect of voting power as of September 30, 2021. The fourth member shall be the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.

Based on the above, the Nomination Committee for the AGM in 2022 has been set up to consist of the following persons, which together represent approximately 30 percent of the number of shares and votes in the Company as of September 30, 2021:
– Saeid Esmaeilzadeh appointed by Serendipity Group AB, the Company´s largest shareholder,
– Ulrik Grönvall appointed by Swedbank Robur Fonder, the Company´s second largest shareholder
– Bengt Göran Westman, the Company´s third largest shareholder
– Anders Tullgren, Chairman of the Company.

Saeid Esmaeilzadeh has been appointed as chairman of the Nomination Committee.

The task of the Nomination Committee is prior to AGM prepare and submit proposals regarding the Chairman of the AGM, candidates for the post of chairman and other directors of the board, fees, and other remuneration for board work to each director, fees to members of committees within the board, election and remuneration of the Company auditor and principles for the nomination committee.

The Nomination Committee's proposal will be presented in the notice to the AGM 2022 and on the Company's website, www.xbrane.com.

Shareholders may submit proposals to the Nomination Committee for the AGM on May 5th, 2022, until January 16, 2022. The proposals can be sent to the following address: Xbrane Biopharma AB Nomination Committee, c/o Xbrane Biopharma AB, Retzius väg 8, 171 65 Solna, Sweden, or via email: valberedning@xbrane.com.

Xbrane's Annual General Meeting will be held in Stockholm on May 5th, 2022.

For further information, please contact:

Anders Tullgren, Chairman of the board
E: valberedning@xbrane.com

Martin Åmark, Chief Executive Officer
M: +46 (0) 763-093 777

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.4bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally two biosimilar candidates in its pipeline targeting € 7.9bn in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.
For more information, visit www.xbrane.com.